Archived from the original on 16 November 2019
Hence, in these cohorts, the eligibility criterion requiring no use of the incretin-based drug of interest and the comparator prior to cohort entry led to a substantial exclusion of patients initiating an incretin-based drug because of a history of previous sulfonylureas use
DeSantis A (2020): Sodium-glucose co-transporter 2 inhibitors for thetreatment of hyperglycemia in type 2 diabetes mellitus
Fang, X., Ardehali, H., Min, J
Here are answers to the most searched questions
Its just you got to kind of know what youre getting yourself into too, when it comes to what is reasonable for a doctor to tell you you need, and at what concentrations you should expect blood level targets to be